Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2021

Open Access 01-12-2021 | IgA Vasculitis | Research article

Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials

Authors: Xue Xue, Xue-han Liu, Chun-li Lu, Xin-yan Jin, Qiang Liu, Xiao-qin Wang, Jian-ping Liu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Login to get access

Abstract

Background

Henoch-Schönlein purpura nephritis (HSPN) is listed as the most common secondary glomerular diseases among children. Approximately 15 to 20% of children eventually could develop into chronic renal failure. Chinese patent herbal medicine Huaiqihuang (HQH) has been widely used in children with HSPN. This study aimed to evaluate the effectiveness and safety of HQH for HSPN in children, so as to provide evidence for clinical use.

Methods

Randomized controlled trials (RCTs) on HQH for HSPN in children were searched in eight Chinese and English databases from their inception to December 2020. We included children with HSPN received HQH combined with conventional medicine. Cochrane “Risk of bias” tool was used to assess methodological quality, and “Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach” to summarize the certainty of evidence for main findings. Effect estimates were presented as risk ratio (RR), mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI) in meta-analyses using RevMan 5.3. Data not suitable for statistical pooling were synthesized qualitatively.

Results

In total seven RCTs were identified. Compared with conventional medicine alone, HQH plus conventional medicine showed the better effect in improving clinical cure rate (RR 1.58; 95%CI 1.17 to 2.14; n = 6) and total effective rate (RR 1.34; 1.16 to 1.54; n = 6); reducing urine sediment erythrocyte count (MD -9.23; − 10.76 to − 7.69; n = 3) and urine β2 micro-globulin level (MD -0.09; − 0.12 to − 0.06; n = 2). No serious adverse event was recorded in all included trials.

Conclusions

Limited evidence showed HQH combined with conventional medicine had a beneficial effect for children with HSPN, and the side effects were mild. HQH may be a promising complementary therapy. However, long term follow-up, high quality and multicenter RCTs are required to confirm the findings.
Literature
1.
Zaffanello M, Brugnara M, Franchini M. Therapy for children with henoch-schonlein purpura nephritis: a systematic review. The Sci World J. 2007;7:20–30.CrossRef
2.
Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA, et al. Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol. 2010;2010:254316.CrossRef
3.
Ding Y, Zhang X, Ren X, Zhai W, He L, Liu J, et al. Traditional Chinese medicine versus regular therapy in Henoch-Schönlein purpura nephritis in children: study protocol for a randomized controlled trial. Trials. 2019;20:538.CrossRef
4.
Wang P, Tang L, Yao J, et al. The spectrum of biopsy-proven secondary glomerular diseases: a cross-sectional study in China. Clin Nephrol. 2017;88:270–6.CrossRef
5.
Shi CC, Peng M, Du YY, et al. The efficacy and safety of integrated Chinese plus Western medicine compared with Western medicine alone in the treatment for purpuric nephritis: a Meta-Aalysis. Science. 2020;8:19–35.
6.
Zou XR, Xue X, Wang CJ, et al. A Chinese cohort study on Henoch-schonlein purpura nephritis: design and methods. Eur J Inflamm. 2018;16:1–6.CrossRef
7.
Cattran DC, Feehally J, Cook HT, et al. Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.CrossRef
8.
Zhang X, Cheng Y, Zhou Q, Huang H, Dong Y, Yang Y, et al. The effect of Chinese traditional medicine Huaiqihuang (HQH) on the protection of nephropathy. Oxidative Med Cell Longev. 2020;16:2153912.
9.
Li LT, Shi MY, Wei SY, et al. Huai qi Huang ameliorates proteinuria and hematuria in mild IgA nephropathy patients: a prospective randomized controlled study. J Formos Med Assoc. 2013;112:766–72.CrossRef
10.
Liu H, Sun W, Tu Y. Mechanism of Huaiqihuang granules delaying chronic kidney disease. Chin Nephrol J Integr Tradit West Med. 2014;15:926–8.
11.
Geng HY, Cao L, Wang W, et al. A prospective, randomized, controlled clinical study of Huaiqihuang granules in treatment of childhood primary nephrotic syndrome. Chin J Contemp Pediatr. 2015;17:31–4.
12.
Du Y, Hu ZJ, Hou L, et al. Clinical observation of Huaiqihuang granules combined with glucocorticoid in treating primary IgA nephropathy in children. Liaoning J Tradit Chin Med. 2018;45:328–31.
13.
Duan CR, Li ZH, Zhang Y, et al. Effects of Huaiqihuang granules on hemorheology and serum hs-CRP in children with HSPN. Guid J Tradit Chin Med Pharm. 2017;23:94–5+8.
14.
Han DX. Clinical observation on treatment of 38 cases of pediatric HSPN with integrated traditional Chinese and conventional medicine. Chin J Ethno Med Pharm. 2014;23:42+4.
15.
Lu W. Effect of Huaiqihuang granules on serum cytokines in children with HSPN. Chin J Pharm Ind. 2015;24:47–9.
16.
Peng YH, Deng LL. Effect of Huaiqihuang granules in treating HSPN and its influence on serum cytokines. J Community Med. 2014;12:10–2.
17.
Shi Z, Weng ZY, Yu L. Clinical study of Huaiqihuang granules combined with glucocorticoid and mycophenolate mofetil in the treatment of children with purpuric nephritis. Int Med Health Guid News. 2019;15:2483–7.
18.
Yuan TT, Zhang RF. The effect of Huaiqihuang granule on children with HSPN and its influence on renal function and immune inflammatory factors. Mod J Integr Tradit West Med. 2020;29:545–8.
19.
Zhou DJ, Wu XC, Wang FJ, et al. The regulating effect of Huaiqihuang on Th17/Treg cell immune imbalance in children with purpuric nephritis. Chin J Pract Pediatr. 2013;5:352–6.
20.
Wang Z, Chen Y, Luo J, et al. Observation of curative effect and mechanism of Huaiqihuang intervention in mouse IgA nephropathy model. Chin Nephrol J Integr Tradit West Med. 2011;12:974–8+1038.
21.
Li T, Mao J, Huang L, Fu H, Chen S, Liu A, et al. Huaiqihuang may protect from proteinuria by resisting MPC5 podocyte damage via targeting p-ERK/CHOP pathway. Bosnian J Basic. 2016;16:193.CrossRef
22.
Sun W, Zhu Z, Yu J, et al. Effect of Huaiqihuang granules on the expression of nephrin and podocin in the renal tissue of rats with adriamycin nephropathy. J Integr Med. 2011;9:546–52.
23.
Lu HY, Zhang QL, Jiang XY, et al. The effect of Huaiqihuang on proteinuria, nephrin and podocin in kidney tissue of rats with IgA nephropathy. Chin J Obstet Gynecol Pediatr. 2009;5:458–65.
24.
Bai J, Geng W, Mei Y, et al. Effect of Huaier on the proliferation of mesangial cells in anti-Thy-1 nephritis. Cell Physiol Biochem. 2017;42:2441–52.CrossRef
25.
Pu J, Zhang Y, Zhou J. Effect of Huai Qi Huang on epithelial-mesenchymal transition of renal tubular epithelial cells through miR-200a. Evid Based Compl Alt. 2016;2016:8612190.
26.
Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRef
27.
Nephrology Group, Pediatrics Society, Chinese Medical Association. Evidence-based guidelines for the diagnosis and treatment of common kidney diseases in children (II): evidence-based guidelines for the diagnosis and treatment of Henoch-Schonlein purpura nephritis. Chin J Pediatr. 2009;47:911–3.
28.
Ye RG, Chen YS, Fang JA. Summary of discussions on diagnosis, treatment and curative effect standards of nephropathy. Chin J IntegrTradit Western Nephrol. 2003;4:355–7.
29.
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.PubMed
30.
Chen W, Fang SN, Liu JP, et al. The development and current situation of international evidence-based medicine evidence classification system. Chin Nephrol J Integr Tradit West Med. 2017;37:1413–9.
31.
32.
Wang N, Liu L, Li CZ, et al. Study on the effect of Huaiqihuang granule on T lymphocyte subsets and urine kidney damage molecule-1 in HSPN. Chin J Pract Pediatr. 2013;28:943–5.
33.
Ma XL. Clinical observation of Huaiqihuang granule in children with Henoch-schonlein purpura nephritis. Hebei Univ Med Sci. 2019;3:1–35.
34.
Yang B, Tan X, Xiong X, et al. Effect of CD40/CD40L signaling on IL-10-producing regulatory B cells in Chinese children with Henoch-Schönlein purpura nephritis. Immunol Res. 2017;65:592–604.CrossRef
35.
Shao X, Jiang C, Li Y, et al. Function of CD4(+) CD25(+) regulatory T cells in Henoch-Schonlein purpura nephritis in children. Chin J Pediatr. 2014;52:516–20.
36.
Fasching P, Stradner M, Graninger W, Dejaco C, Fessler J. Therapeutic potential of targeting the Th17/Treg Axis in autoimmune disorders. Molecules. 2017;22:134.CrossRef
37.
Chen O, Zhu XB, Ren H, et al. The imbalance of Th17/Treg in Chinese children with Henoch-Schonlein purpura. Int Immunopharmacol. 2013;16:67–71.CrossRef
38.
Xue X, Liu Q, Wang XQ, et al. Correlation between expression of Treg/Th17 cell Axis in peripheral blood and TCM syndrome type in adults with HSPN patients. Mod Tradit Chin Mater Med—World Sci Technol. 2020;22:2907–13.
39.
Shao XS, Jiang C, Li YH, et al. Study on the function of CD4+CD25+ regulatory T cells in children with purpuric nephritis. Chin J Pediatr. 2014;52:516–20.
Metadata
Title
Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
Authors
Xue Xue
Xue-han Liu
Chun-li Lu
Xin-yan Jin
Qiang Liu
Xiao-qin Wang
Jian-ping Liu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-021-03415-x

Other articles of this Issue 1/2021

BMC Complementary Medicine and Therapies 1/2021 Go to the issue

Research article

A systematic review and quality assessment of complementary and alternative medicine recommendations in insomnia clinical practice guidelines

Research article

Antitumor activities of Aspiletrein A, a steroidal saponin from Aspidistra letreae, on non-small cell lung cancer cells

Research article

Problems with the outcome measures in randomized controlled trials of traditional Chinese medicine in treating chronic heart failure caused by coronary heart disease: a systematic review

Research article

Anti-inflammatory effects of Morus alba Linne bark on the activation of toll-like receptors and imiquimod-induced ear edema in mice

Research article

Anti-osteoarthritis potential of peppermint and rosemary essential oils in a nanoemulsion form: behavioral, biochemical, and histopathological evidence

Research

Metagenomic and phytochemical analyses of kefir water and its subchronic toxicity study in BALB/c mice